Please try another search
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Name | Age | Since | Title |
---|---|---|---|
Pini Orbach | 59 | 2023 | Director |
Murray A. Goldberg | 79 | 2023 | Director |
Roni A. Appel | 57 | 2023 | Director |
Vered Bisker-Leib | 52 | 2023 | Director |
Robert Jay Spiegel | 75 | 2023 | Director |
Bridget Ann Martell | 58 | 2023 | Director |
David Sidransky | 64 | 2023 | Chairman |
Yuval Cabilly | 44 | 2023 | Director |
Kenneth A. Berlin | 60 | 2023 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review